# Aminoglycoside Resistance Among Clinical Bacterial Isolates in Sétif, Algeria: Epidemiology, Multidrug Resistance, and Virulence Features

**Authors:** Anfal Kara, Chiara Massaro, Naouel Boussoualim, Giovanni M. Giammanco, Rosa Alduina, Zineb Daoudi, Noussaiba Douadi, Fatma Gridi, Mohammad Raish, Byong-Hun Jeon, Hyun-Jo Ahn, Yacine Benguerba

PMC · DOI: 10.3390/antibiotics15020222 · Antibiotics · 2026-02-17

## TL;DR

This study examines aminoglycoside-resistant bacteria in Algeria, finding high resistance rates and multidrug resistance patterns among clinical isolates.

## Contribution

The study provides a detailed epidemiological and resistance profile of aminoglycoside-resistant bacteria in Setif, Algeria.

## Key findings

- Aminoglycoside resistance was more common in female patients and adults, with urinary tract infections being the main clinical presentation.
- High resistance rates were observed for several antibiotics, while chloramphenicol and imipenem showed better effectiveness.
- Multidrug resistance was present in 25.6% of isolates, with cross-resistance between gentamicin and β-lactam antibiotics.

## Abstract

Background. Antibiotic resistance is a growing global health challenge, complicating the management of infections. Aminoglycosides are increasingly associated with resistance, raising the risk of clinical complications and mortality in severe infections. This study aimed to characterize the epidemiological profile of 135 aminoglycoside-resistant clinical strains collected in Setif between 2021 and 2023. Methods. Antibiotic susceptibility testing was performed according to EUCAST guidelines, and phenotypic assays were conducted to assess key virulence traits, including biofilm formation and enzyme production. Results. Aminoglycoside resistance was more frequently observed in female patients (55.6%) and was found to be predominant among adults (68.1%). Urinary tract infections represented the main clinical presentation (76.3%), with Escherichia coli being the most common isolate (40.7%). High resistance rates were detected for amoxicillin (83%), amoxicillin–clavulanic acid (80%), cephalexin (74.8%), cefixime (71.1%), trimethoprim–sulfamethoxazole (74.8%), and gentamicin (72.6%). Conversely, chloramphenicol (53.3%), imipenem (47.4%), amikacin (47.4%), and piperacillin–tazobactam (31.1%) remained comparatively more effective. Multidrug resistance involving seven antibiotics occurred in 25.6% of isolates, with notable cross-resistance patterns between gentamicin and β-lactam antibiotics (5 out of 22). Genotypic analysis showed that 43% of isolates carried at least one β-lactamase gene, whereas 9.6% harbored a qnr determinant. Regarding virulence factors, isolates with low biofilm-forming ability were found to be the most common (62.96%). Conclusion. In conclusion, this study revealed substantial variations in aminoglycoside resistance in Setif, shaped by demographic, clinical, and bacteriological factors.

## Linked entities

- **Chemicals:** amoxicillin (PubChem CID 33613), amoxicillin–clavulanic acid (PubChem CID 6435924), cephalexin (PubChem CID 27447), cefixime (PubChem CID 5362065), trimethoprim–sulfamethoxazole (PubChem CID 358641), gentamicin (PubChem CID 3467), chloramphenicol (PubChem CID 5959), imipenem (PubChem CID 104838), amikacin (PubChem CID 37768), piperacillin–tazobactam (PubChem CID 461573)
- **Species:** Escherichia coli (taxon 562)

## Full-text entities

- **Genes:** CAT (catalase) [NCBI Gene 847], beta-Lactamase [NCBI Gene 7872529], beta-lactamase [NCBI Gene 4290808]
- **Diseases:** Infections (MESH:D007239), COVID-19 (MESH:D000086382), Urinary tract infections (MESH:D014552), nosocomial infections (MESH:D003428), deaths (MESH:D003643), infectious diseases (MESH:D003141), sepsis (MESH:D018805), bacterial infections (MESH:D001424), -negative bacilli (MESH:D064726), diabetes (MESH:D003920), injury to (MESH:D014947), MDR (MESH:D018088), hemolysis (MESH:D006461)
- **Chemicals:** Cephalosporins (MESH:D002511), piperacillin+ tazobactam (MESH:D000077725), CL (MESH:D002713), quinolone (MESH:D015363), AK (MESH:D000583), fluoroquinolones (MESH:D024841), Hektoen agar (-), CTX (MESH:D002439), crystal violet (MESH:D005840), ATM (MESH:D001398), K (MESH:D011188), CN (MESH:D002506), penicillins (MESH:D010406), glycerol (MESH:D005990), fosfomycin (MESH:D005578), beta-lactam (MESH:D047090), LEV (MESH:D007978), indole (MESH:C030374), Chloramphenicol (MESH:D002701), glucose (MESH:D005947), OF (MESH:D015242), ticarcillin + clavulanic acid (MESH:C043215), IMP (MESH:D015378), mannitol (MESH:D008353), clavulanic acid (MESH:D019818), polystyrene (MESH:D011137), citrate (MESH:D019343), CFM (MESH:D020682), sucrose (MESH:D013395), agarose (MESH:D012685), trimethoprim-sulfamethoxazole (MESH:D015662), lactose (MESH:D007785), AMC (MESH:D019980), sulfonamide (MESH:D013449), agar (MESH:D000362), CIP (MESH:D002939), C (MESH:D002244), cefoxitin (MESH:D002440), saline (MESH:D012965), methanol (MESH:D000432), Aminoglycoside (MESH:D000617), FEP (MESH:D011138), PRL (MESH:D010878), TC (MESH:D013667), TOB (MESH:D014031), tazobactam (MESH:D000078142), gentamicin (MESH:D005839), Kanamycin (MESH:D007612), AMX (MESH:D000658), ethanol (MESH:D000431), water (MESH:D014867), ticarcillin (MESH:D013982), NA (MESH:D009268), CAZ (MESH:D002442), Carbapenems (MESH:D015780), cefepime (MESH:D000077723), LE (MESH:D064704)
- **Species:** Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Homo sapiens (human, species) [taxon 9606], Morganella morganii (species) [taxon 582], Enterobacteriaceae (enterobacteria, family) [taxon 543], Serratia marcescens (species) [taxon 615], Pseudomonas aeruginosa (species) [taxon 287], Klebsiella pneumoniae (species) [taxon 573], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Bacillus cereus (species) [taxon 1396], Escherichia coli (E. coli, species) [taxon 562], Enterobacter (genus) [taxon 547], Enterobacterales (order) [taxon 91347]
- **Cell lines:** ATCC 29213 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12937654/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12937654/full.md

## References

63 references — full list in the complete paper: https://tomesphere.com/paper/PMC12937654/full.md

---
Source: https://tomesphere.com/paper/PMC12937654